文献速递支持与姑息治疗

哌甲酯与安慰剂治疗晚期癌症患者疲劳的比较:随机、双盲、多中心、安慰剂对照试验

Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial.
PubMed 文献 · J Clin Oncol · 2024-05-17

该随机双盲多中心安慰剂对照试验纳入162例晚期不可治愈癌症且疲劳评分>3/10的患者,比较个体化剂量滴定哌甲酯与安慰剂6周对疲劳的影响。主要结局显示6±2周时哌甲酯组FACIT-F评分较安慰剂组高1.97分(95%CI -0.95至4.90,P=0.186),差异无统计学意义;哌甲酯安全且耐受良好。

要点

  • 6±2周时哌甲酯组FACIT-F评分较安慰剂组高1.97分(95%CI -0.95至4.90,P=0.186),未达统计学显著。
  • 10周内哌甲酯组FACIT-F名义上高于安慰剂组(差值2.20,95%CI 0.39至4.01),但未达最小临床重要差异5分。
  • 6周时除抑郁评分在哌甲酯组名义上降低(差值-1.35,95%CI -2.41至-0.30)外,生活质量或症状域无组间差异。

核心结论

  • 6±2周治疗后,哌甲酯治疗晚期癌症疲劳不优于安慰剂;哌甲酯安全且耐受良好。

研究设计与样本

  • 随机、双盲、安慰剂对照、多中心试验;纳入晚期不可治愈癌症且疲劳>3/10的患者,排除高血压、精神/心血管/脑血管/肾/肝/血液疾病、物质依赖及癫痫。
  • 162例患者随机1:1分配至哌甲酯或安慰剂,起始5 mg每日两次,每周滴定一次共6周,最大20 mg每日三次,试验至10周;3例排除分析。
  • 主要结局为6±2周时组间FACIT-F评分差异;次要结局包括不良事件、生活质量和情绪。

主要发现

  • 6±2周时哌甲酯组FACIT-F评分较安慰剂组高1.97分(95%CI -0.95至4.90,P=0.186),未达统计学显著。
  • 10周内哌甲酯组FACIT-F名义上高于安慰剂组(差值2.20,95%CI 0.39至4.01),但未达最小临床重要差异5分。
  • 6周时除抑郁评分在哌甲酯组名义上降低(差值-1.35,95%CI -2.41至-0.30)外,生活质量和症状域无组间差异。
  • 死亡率和严重不良事件无组间差异。

关键数值与推荐

  • 疲劳纳入标准:>3/10。
  • 哌甲酯/安慰剂起始剂量5 mg每日两次,每周滴定一次共6周,最大20 mg每日三次。
  • 主要结局评估时间:6±2周。

临床怎么用

  • 原文结论为哌甲酯治疗晚期癌症疲劳不优于安慰剂,未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare effects and side effects of 6 weeks of individually dose-titrated methylphenidate or placebo on fatigue in palliative care patients with advanced cancer. METHODS: This is a randomized, double-blind, placebo-controlled, multicenter trial. Eligible patients had advanced incurable cancer and fatigue >3/10. Principal exclusions were hypertension; psychiatric, cardiovascular, cerebrovascular, renal, liver, or blood disorders; substance dependency; and epilepsy. Patients were randomly assigned 1:1 methylphenidate or placebo starting at 5 mg twice daily. Dose of methylphenidate/placebo was titrated once per week, over 6 weeks, up to a maximum of 20 mg three times daily. Trial ended at 10 weeks. Primary outcome was the difference in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) scores between groups at 6 ± 2 weeks. Secondary outcomes included adverse effects, quality of life, and mood. RESULTS: One hundred sixty-two patients (73 men; mean, 65.8; standard deviation [SD], 10.3 years) were randomly assigned, and three were excluded from analysis. Seventy-seven were allocated placebo (baseline FACIT-F = 22 [SD, 10]); 82 were allocated methylphenidate (FACIT-F = 20 [SD, 9]). After 6 ± 2 weeks, FACIT-F scores were 1.97 points (95% CI, -0.95 to 4.90; P = .186) higher (better) on methylphenidate than placebo. Across 10 weeks of the study, FACIT-F was nominally higher in the methylphenidate group versus placebo (Diff, 2.20 [95% CI, 0.39 to 4.01]), but this did not reach the minimally clinically important difference (5-points). At 6 weeks, there were no differences between groups in quality-of-life or symptom domains except for depression scores (nominally reduced in the methylphenidate group: Diff, -1.35 [95% CI, -2.41 to -0.30]). There were no differences in mortality or serious adverse events. CONCLUSION: After 6 ± 2 weeks of treatment, methylphenidate was not superior to placebo for treating fatigue in advanced cancer. Methylphenidate was safe and well-tolerated.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Stone PC, Minton O, Richardson A, et al. Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial. J Clin Oncol. 2024. PMID: 38757263. doi:10.1200/JCO.23.02639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。